« Return to News | Awards & Advancement

Quintiles receives Computerworld Data+ Editor's Choice Award

Thursday, August 29, 2013 01:00 PM

CRO Quintiles has been recognized for its pioneering work creating big data solutions that help pharmaceutical organizations improve their probability of success throughout the drug development process, with a Computerworld Data+ Editor's Choice Award for its Quintiles Infosario platform.

"The drug development process is predicated upon the availability of high-quality data with which to collaborate and make informed decisions at every step of the way during the evolution of a product or treatment," said Richard Thomas, Quintiles chief information officer.

Quintiles Infosario is an end-to-end suite of technologies that power the pharmaceutical product development process. Infosario is able to break down silos combining massive quantities of scientific and operational data collected during clinical development with tens of millions of real-world patient medical records and population data. Providing researchers and drug developers with the knowledge in this data improves decision making and, ultimately, increases the probability of success of a product's lifecycle.

Computerworld's Data+ awards recognize projects that illustrate how big data can be mined and analyzed to predict trends and improve the probability of success.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.